Having a Negative MRI Does Not Mean That You Don't Have a Significant Cancer.
Dr. Todd Cohen, former CEO of Carolina Urology Partners and Medical Director of Myriad Urology, brings you a casual, yet educational podcast about modern topics in Urology. Because every man with prostate cancer deserves a better answer.
In this episode, The Modern Urologist sits down with Dr. David Morris, from Urology Associates P.C. in Tennessee to talk about the history of MRI and the impact it can have on biopsy and surgical planning. Dr. Morris further discusses societal MRI guidelines, the utilization in mainstream urology and how he personally uses this technology in his treatment of prostate cancer. The limitations of using MRI to risk stratify patients is discussed
The conversation then turns to compliance tracking and protocols as a way for urology practices to improve their active surveillance protocols and how genomic tests can help providers feel confident when placing a patient on active surveillance.
Dr. David Morris discusses the evolution of MRI in prostate cancer and reviews scenarios where MRI may be best suited. The impact MRI has on biopsy effectiveness, surgical planning decisions, and the limitations that can arise from using MRI to risk stratify patients are discussed. Dr. Morris also shares his personal experience and preference on how he uses MRI in his practice.
In addition to MRI, Dr. Morris gives suggestions on how to improve active surveillance protocols, compliance tracking, and how genomic testing can physicians’ additional reassurance when placing a patient on active surveillance.